PubMed · 11712408
[KRP-297, MCC-555].
Abstract
KRP-297 and MCC-555, which are being developed in Japan as thiazolidinediones, uniquely bind and activate peroxisome proliferator-activated receptors(PPAR). KRP-297, unlike other thiazolidinediones, effects on not only PPAR gamma but also PPAR alpha. Furthermore, this compound acts directly on basal glucose uptake in the rat skeletal muscle. KRP-297 decreased plasma glucose and insulin levels, and also blood triglyceride and free fatty acid in diabetic animal models. MCC-555 has significant antidiabetic properties yet its binding affinity for PPAR gamma is less than 1/10 that of BRL 49653. Thus, it is regarded now as a PPAR gamma modulator rather than agonist, depending on cell type. At present, clinical phase II studies of both drugs are under way.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
T Yamanouchi. 2001. [KRP-297, MCC-555].. https://pubmed.ncbi.nlm.nih.gov/11712408/
Cite the original work for its findings. Save a collection to share your selection of sources.